Of the few studies on targeted drugs that include mesothelioma, most late-stage studies are focused on BAP1 mutations while inactivating NF2 mutations (and other hippo pathway mutations) are more prevalent in pleural mesothelioma patients. The gene discussed is BAP1; the disease is pleural mesothelioma.